GEDEON RICHTER RUS JSC

Clarification: GEDEON RICHTER RUS JSC is the Russian subsidiary of Gedeon Richter Plc, a Hungarian multinational pharmaceutical and biotechnology company. It primarily operates within Russia and is not an Indian company. Gedeon Richter Plc, the parent company, does have a presence and conducts business in India through its global operations.

Company Type: Manufacturer and Trader/Distributor

Company Introduction:

GEDEON RICHTER RUS JSC is an integral part of Gedeon Richter Plc, a prominent pharmaceutical company headquartered in Hungary with a rich history in drug research, development, manufacturing, and sales.

Within Russia, GEDEON RICHTER RUS JSC functions as both a manufacturer and a trader/distributor. It operates local production facilities where it manufactures various pharmaceutical formulations, contributing to the supply of medicines within the Russian Federation. Simultaneously, it serves as the primary entity responsible for the marketing, sales, and distribution of Gedeon Richter's extensive portfolio of pharmaceutical products across Russia. This dual role allows it to leverage local production capabilities while also efficiently bringing a broad range of globally developed medicines to the Russian market.

GEDEON RICHTER RUS JSC, the Russian subsidiary, does not directly manufacture or sell products in India.

However, products from its parent company, Gedeon Richter Plc. (headquartered in Hungary), are sold in India through its local operations. The main therapeutic areas and examples of Gedeon Richter products available in India typically include:

Women's Healthcare:

Oral Contraceptives

Emergency Contraceptives such as Postinor and Escapelle

Hormone Replacement Therapy products

Central Nervous System Disorders:

Medications for conditions like schizophrenia and bipolar disorder, including Cariprazine (marketed under various brand names globally)

Cardiovascular Diseases:

Products for managing heart and circulatory conditions

Other therapeutic areas may also be covered by their portfolio in India.